Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145141 · ClinicalTrials.gov registry record
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
A clinical trial of Hepatocellular Carcinoma and Liver Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 500
- Enrollment target
- 7
- Study locations
NCT04145141 is a study of Hepatocellular Carcinoma and Liver Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 500 participants, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher). The trial reports 7 study locations across 6 states.
The verdict
NCT04145141, a study of Hepatocellular Carcinoma and Liver Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 7
- Study locations
Study Summary
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their medical records. They will be asked about their medical history and test results. Participants will come to the NIH Clinical Center. During this visit, their medical records, test results, imaging studies, and tissue samples (if available) will be gathered. Participants will learn the results of a test to see if they have any mutations known to be connected to cancer. They will learn if there are treatment options for them. Participants will give blood, urine, and stool samples or rectal swabs. Participants will not have follow-up visits just for this study. If they join another NIH research study and have visits for this other study, their medical records; test results; and blood, urine, and stool samples may be collected. This will occur about every 3 months. If they have a biopsy or surgery on another study or as part of treatment and there is leftover tissue, researchers would like to collect some of that tissue. Participants will be contacted every 6 months by phone or e-mail. They will be asked about their health. They will provide any medical records, test results, and imaging studies. Participants will be followed on this study for life.
Conditions Studied
Study Locations (7)
California
- University of California, San Diego (UCSD) - La Jolla
- University of California, San Francisco (UCSF) - San Francisco
District of Columbia
- Georgetown University - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145141
The ClinicalTrials.gov registry entry for NCT04145141 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04145141 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT04145141 about?
NCT04145141 is a clinical study titled "National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer". Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better ...
What is the current status of trial NCT04145141?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-07-28. Estimated completion is 2027-12-31.
What conditions does trial NCT04145141 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma.
Who is sponsoring clinical trial NCT04145141?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04145141 being conducted?
This trial has 7 study locations across California, District of Columbia, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.